BR112013004662B8 - Compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition - Google Patents

Compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition

Info

Publication number
BR112013004662B8
BR112013004662B8 BR112013004662A BR112013004662A BR112013004662B8 BR 112013004662 B8 BR112013004662 B8 BR 112013004662B8 BR 112013004662 A BR112013004662 A BR 112013004662A BR 112013004662 A BR112013004662 A BR 112013004662A BR 112013004662 B8 BR112013004662 B8 BR 112013004662B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
preparing
compounds
agonists
Prior art date
Application number
BR112013004662A
Other languages
Portuguese (pt)
Other versions
BR112013004662B1 (en
BR112013004662A2 (en
Inventor
Angel Messeguer
Pablo Villoslada
Original Assignee
Bionure Farma S L
Consejo Superior Investigacion
Inst Dinvestigacions Biomediques August Pi I Sunyer Ibibaps
Inst Dinvestigacions Biomediques August Pi I Sunyer Idibaps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionure Farma S L, Consejo Superior Investigacion, Inst Dinvestigacions Biomediques August Pi I Sunyer Ibibaps, Inst Dinvestigacions Biomediques August Pi I Sunyer Idibaps filed Critical Bionure Farma S L
Publication of BR112013004662A2 publication Critical patent/BR112013004662A2/en
Publication of BR112013004662B1 publication Critical patent/BR112013004662B1/en
Publication of BR112013004662B8 publication Critical patent/BR112013004662B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica. a invenção refere-se aos compostos de fórmula (i) ; e sais farmaceuticamente aceitáveis dos mesmos, em que r1, r2 e r3 são definidos conforme estabelecido no relatório descritivo. os compostos são agonistas de receptores de neurotrofina (tal como fator de crescimento neural).compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition. the invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are defined as set out in the specification. the compounds are agonists of neurotrophin receptors (such as neural growth factor).

BR112013004662A 2010-08-31 2011-08-31 Compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition BR112013004662B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37882310P 2010-08-31 2010-08-31
US61/378,823 2010-08-31
PCT/IB2011/002562 WO2012028959A1 (en) 2010-08-31 2011-08-31 Agonists of neurotrophin receptors and their use as medicaments

Publications (3)

Publication Number Publication Date
BR112013004662A2 BR112013004662A2 (en) 2016-08-02
BR112013004662B1 BR112013004662B1 (en) 2021-09-28
BR112013004662B8 true BR112013004662B8 (en) 2022-02-08

Family

ID=45048148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004662A BR112013004662B8 (en) 2010-08-31 2011-08-31 Compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition

Country Status (19)

Country Link
US (3) US8791076B2 (en)
EP (1) EP2611775B8 (en)
JP (1) JP5946454B2 (en)
KR (1) KR101964954B1 (en)
CN (1) CN103270022B (en)
AU (1) AU2011298091B2 (en)
BR (1) BR112013004662B8 (en)
CA (1) CA2809774C (en)
DK (1) DK2611775T3 (en)
ES (1) ES2575684T3 (en)
HR (1) HRP20160553T1 (en)
HU (1) HUE029393T2 (en)
IL (1) IL224972A (en)
MX (1) MX340233B (en)
PL (1) PL2611775T3 (en)
PT (1) PT2611775E (en)
RU (1) RU2606622C2 (en)
SI (1) SI2611775T1 (en)
WO (1) WO2012028959A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
EP2611775B8 (en) 2010-08-31 2016-06-08 Bionure Farma, S.L. Agonists of neurotrophin receptors and their use as medicaments
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
ES2699410T3 (en) * 2014-05-28 2019-02-11 Univ Dresden Tech Cell-based assay and methods of screening modulators of p75NTR signaling
US20190231787A1 (en) * 2016-08-25 2019-08-01 Pharmatrophix, Inc. Methods and compounds for treating alcohol use disorders and associated diseases
KR101821118B1 (en) 2016-09-06 2018-01-23 가톨릭대학교 산학협력단 Composition for Preventing or Treating Allergic Disease Comprising Gambogic Acid
CN107802823A (en) * 2017-10-27 2018-03-16 胡军 Application of function of the SH2B adaptins 1 in Parkinson's are treated
CA3105879A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
UA127872C2 (en) 2018-12-05 2024-01-31 Скохія Фарма, Інк. Macrocyclic compound and use thereof
TW202116297A (en) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 Combination therapy methods, compositions and kits
TW202131914A (en) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 New treatment regimen for the treatment of neurological diseases or conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5747458A (en) 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (en) 1997-11-18 1999-07-08 Univ Ludwigs Albert 4-substituted 2-pyrrolidinone derivatives to reduce extracellular glutamate levels
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
CZ304308B6 (en) 2000-05-04 2014-02-26 Basf Aktiengesellschaft Uracil substituted phenylsulfamoyl carboxamides, process of their preparation and herbicidal composition containing them
ES2169690B1 (en) * 2000-10-06 2004-03-16 Diverdrugs Sl QUARTERS OF N-ALQUILGLICINA CAPABLE OF PROTECTING NEURONS AGAINST EXCITOTOX AGGRESSIONS, AND COMPOSITIONS CONTAINING THEM.
ES2169691B1 (en) * 2000-10-11 2004-03-16 Diverdrugs Sl N-ALQUILGLYCIN QUARTERS ABLE TO BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES, THERMAL STIMULES OR MEDIATORS OF THE INFLAMMATION OF NEURONAL RECEPTORS, AND COMPOSITIONS CONTAINING THEM.
AU2003280117B2 (en) 2002-11-20 2009-09-10 Newron Sweden Ab Compounds and methods for increasing neurogenesis
DE10303229B4 (en) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol and Angiotensin Converting Enzyme (ACE) inhibitors Drugs and their use in the treatment of neurodegenerative diseases
WO2008040087A1 (en) 2006-10-06 2008-04-10 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and agents useful for same
EP1994944A1 (en) * 2007-05-21 2008-11-26 Laboratorios SALVAT, S.A. Polymer conjugate compounds for the inhibition of apoptosis
AU2009297626B2 (en) 2008-09-24 2016-01-14 Fujimoto Pharmaceutical Corporation Aptamer for NGF and use thereof
RU2410392C2 (en) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Dipeptide mimetics of ngf and bdnf neurotrophins
EP2289882A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
EP2289886A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
EP2611775B8 (en) 2010-08-31 2016-06-08 Bionure Farma, S.L. Agonists of neurotrophin receptors and their use as medicaments

Also Published As

Publication number Publication date
US8791076B2 (en) 2014-07-29
HRP20160553T1 (en) 2016-09-23
CA2809774A1 (en) 2012-03-08
US20150005239A1 (en) 2015-01-01
CN103270022B (en) 2015-08-19
AU2011298091A1 (en) 2013-04-18
EP2611775A1 (en) 2013-07-10
HUE029393T2 (en) 2017-03-28
KR20130106384A (en) 2013-09-27
BR112013004662B1 (en) 2021-09-28
RU2606622C2 (en) 2017-01-10
MX340233B (en) 2016-07-01
EP2611775B8 (en) 2016-06-08
US20120052094A1 (en) 2012-03-01
SI2611775T1 (en) 2017-01-31
AU2011298091B2 (en) 2015-08-20
ES2575684T3 (en) 2016-06-30
MX2013002329A (en) 2013-07-29
CN103270022A (en) 2013-08-28
US9453047B2 (en) 2016-09-27
EP2611775B1 (en) 2016-03-16
PT2611775E (en) 2016-06-07
US20170121367A1 (en) 2017-05-04
BR112013004662A2 (en) 2016-08-02
DK2611775T3 (en) 2016-06-27
US10106577B2 (en) 2018-10-23
JP2013536833A (en) 2013-09-26
KR101964954B1 (en) 2019-04-03
PL2611775T3 (en) 2016-11-30
JP5946454B2 (en) 2016-07-06
RU2013113634A (en) 2014-10-10
WO2012028959A1 (en) 2012-03-08
CA2809774C (en) 2019-03-05
IL224972A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
BR112013004662B8 (en) Compound, pharmaceutical composition, uses of a compound, and method of preparing a pharmaceutical composition
PH12020550552A1 (en) Inhibitors of hepatitis c virus
BR112014018959A8 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, USES OF A COMPOUND AND METHODS FOR THE TREATMENT OF CANCER
CU20140110A7 (en) HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS
BR112014010576B8 (en) neprilisin inhibitor compounds (nep), their uses, process of preparing the compounds and pharmaceutical composition comprising the compounds
MX342212B (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
BR112014007134A2 (en) uses of a compound of formula (b), compounds, pharmaceutical composition, method of preparing the compound and use of an effective amount of a compound
BR112014008495B8 (en) PROTEIN KINASE INHIBITORY COMPOUND, PHARMACEUTICAL COMPOSITION INCLUDING IT AND USE THEREOF FOR THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF CANCER
BR112014018990A8 (en) BENZOTHIAZOLE-6-ILACETIC ACID DERIVATIVES AND THEIR USE FOR TREATMENT OF AN INFECTION
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BR112013011580A2 (en) amino substituted bisphenyl pentanoic acid derivatives as nep inhibitors
EA201591195A1 (en) NEW QUINOLON DERIVATIVES
IN2014CN04530A (en)
BR112015008037A2 (en) compounds, process for preparing a compound, pharmaceutical composition, use of the compound, method for treating cancer and invention
CL2013002861A1 (en) Analog compounds of epoxyeicosatrienoic acid, ethers agonists; pharmaceutical composition; and use of the compounds to prepare useful medications to treat hypertension and induced nephrotoxicity medications, such as cisplatin.
EA201391525A1 (en) GLYCOSIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF DIABETES
EA201591499A1 (en) SUBSTITUTED BISPHENYLBUTANE DERIVATIVES OF PHOSPHONE ACID AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE)
BR112014001083A8 (en) compound, process for preparing a compound, pharmaceutical composition, method for treating diseases and use of a compound
BR112013019160A2 (en) new compounds, pharmaceutical composition, use, processes and methods
BR112013030391A2 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
BR112013017362A2 (en) compound of formula (i), process for preparing a compound of formula (i), pharmaceutical composition and innovative compounds, methods and uses
ECSP13012548A (en) OXADIAZOL INHIBITORS OF LEUCOTRENE PRODUCTION.
BR112012019866A8 (en) COMPOUND, USE THEREOF, PHARMACEUTICAL COMPOSITION, AND PROCESS FOR PREPARING A COMPOUND
BR112013027982A2 (en) isoindolinone derivatives

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIONURE FARMA, S.L. (ES)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIONURE FARMA, S.L. (ES) , INSTITUT D'INVESTIGACIO

B25D Requested change of name of applicant approved

Owner name: BIONURE FARMA, S.L. (ES) ; CONSEJO SUPERIOR DE INV

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AO ENDERECO DE UM DOS TITULARES

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AO ENDERECO DE UM DOS TITULARES

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2647 DE 28/09/2021 QUANTO AO ENDERECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2647, QUANTO AOS NOMES DOS TITULARES